Each of the ten Distinguished Investigator Grants offers $100,000 for a one-year period, targeting projects that focus on a range of debilitating disorders such as depression, autism spectrum disorder (ASD), post-traumatic stress disorder (PTSD), bipolar disorder, schizophrenia, cocaine use disorder, and chronic cannabis use. This funding initiative is a vital component of WoodNext’s five-year $5 million commitment to BBRF’s programs, underscoring the priority placed on unearthing transformative insights into mental illness.

Jeffrey Borenstein, M.D., President and CEO of BBRF, emphasizes the urgency of these studies by highlighting the vast impact of mental illness globally and the persistent gaps in our biological understanding of these disorders. According to Dr. Borenstein, these grants facilitate research that challenges conventional paradigms, potentially redefining diagnostic criteria, enhancing monitoring techniques, and paving the way for innovative treatments that could significantly alter patient outcomes.

The WoodNext Foundation, led by Executive Director Nancy Chan, stresses the importance of supporting high-impact scientific endeavors that push the bounds of current knowledge. They believe that such bold research efforts are essential in unlocking novel therapeutic avenues and ultimately improving lives affected by mental health conditions.

Among the notable recipients, Dr. Ravi Allada from the University of Michigan is investigating the intricate biological interplay between bipolar disorder and the regulation of circadian rhythms and sleep. His work aims to identify biomarkers that could refine diagnosis and treatment – a thorough molecular mapping of risk genes to functional clinical phenotypes could revolutionize how the psychiatric community assesses and manages bipolar disorder, potentially integrating circadian-based therapeutic modalities such as timed light exposure and melatonin administration.

At Harvard University, Dr. Paola Arlotta leverages cutting-edge human brain organoid technology to model early developmental disruptions associated with ASD. By studying the asynchronous maturation of inhibitory neurons relative to their excitatory counterparts, her research delves into the cellular and circuit-level abnormalities that might underlie the diverse manifestations of autism across different genetic risk profiles. The project will test hypotheses regarding the neural circuitry disruption caused by mutations in genes such as ARID1b, deepening our understanding of ASD pathogenesis at a fundamental level.

Dr. Christopher W. Cowan from the Medical University of South Carolina is pioneering an RNA-based therapeutic approach to treat MEF2C haploinsufficiency syndrome (MCHS), a single-gene disorder with profound neurodevelopmental consequences including autism-like symptoms, language impairment, and seizures. His research not only sheds light on the molecular underpinnings of this rare but debilitating syndrome but also has broader implications for bipolar disorder, major depressive disorder, and schizophrenia, all of which show genetic correlation with MEF2C variants.

Addressing PTSD, Dr. Aline Desmedt at INSERM in France has innovated an animal model that accurately captures the dual facets of pathological trauma memory: traumatic hypermnesia and contextual amnesia. This critical distinction allows for a refined exploration of the neurobiological mechanisms regulating the transformation between normative fear memories and pathological trauma responses. Her work could illuminate novel targets for therapeutic intervention aimed at preventing or reversing the intrusive and debilitating memories characteristic of PTSD.

Cocaine use disorder (CUD) is the focus of Dr. Karen D. Ersche’s research at the University of Cambridge, where she investigates the role of neuroendocrine disruptions impacting decision-making and emotional regulation. This research explores how imbalances in the hypothalamic–pituitary–adrenal and hypothalamic–pituitary–gonadal axes influence brain regions such as the amygdala and orbitofrontal cortex. Understanding the link between hormonal dysregulation and maladaptive behaviors in CUD could herald new pharmacological or behavioral treatment strategies.

The intersection of gene expression and neuropsychiatric disorders is a frontier explored by Dr. Stephen J. Glatt at SUNY Upstate Medical University, who is developing BrainGENIE+, an advanced algorithm to non-invasively infer gene expression across multiple brain regions via blood samples. This methodological breakthrough promises not only to trace molecular dynamics during disease onset, progression, and recovery but also to establish comprehensive atlases of gene expression linked to brain health and pathology.

UCLA’s Dr. Alicia Izquierdo investigates the neurocircuitry underlying schizophrenia by dissecting how the brain distinguishes between environmental volatility—the rate at which external conditions change—and stochasticity, the random noise inherent in these conditions. Her focus on thalamo-frontocortical networks and their role in modulating these perceptions is expected to illuminate how impaired volatility processing contributes to paranoia and psychosis, offering new avenues for targeted neuromodulation therapies.

At the Medical University of South Carolina, Dr. Wei Jiang focuses on the paradoxical association of chronic cannabis use with anxiety, depression, and suicidality. His research zeroes in on the peripheral contributions to central nervous system dysfunction, particularly how alterations in the oral microbiome, specifically Actinomyces species, might drive mitochondrial dysfunction and disturbed neurotransmission, thus influencing emotional states in chronic users.

Dr. Loren L. Looger from UC San Diego explores an underappreciated pharmacological mechanism for antidepressant effects: the intracellular upregulation of serotonin synthesis. While selective serotonin reuptake inhibitors (SSRIs) act extracellularly, recent findings suggest psychedelics and MDMA may boost serotonin synthesis within neurons, enhancing therapeutic outcomes. Dr. Looger’s high-throughput screen aims to identify novel compounds that modulate this intracellular pathway, potentially revolutionizing antidepressant drug design beyond conventional modalities.

Finally, Dr. Jamie L. Maguire at Tufts University addresses the pressing issue of treatment-resistant depression by developing therapies targeting neurosteroid synthesis. These endogenous compounds possess documented anxiolytic and antidepressant properties, and by enhancing their biosynthesis, her team aims to craft transdiagnostic interventions with the potential to dramatically expand the therapeutic arsenal for psychiatric illnesses.

The BBRF and its Allied WoodNext Foundation collectively underscore a fundamental commitment: 100% of funds donated for research are reinvested exclusively into scientific projects, ensuring the most effective use of philanthropic resources. This model has empowered the Foundation to grant over $476 million to more than 5,700 investigators since 1987, fostering innovation and hope within the mental health community. Through sustained investment in high-risk, high-reward research, these grants propel the scientific community toward breakthroughs that could redefine mental health diagnostics, therapeutics, and ultimately, patient recovery worldwide.

Subject of Research: Neurobiological and behavioral research into major mental health disorders including depression, autism spectrum disorder, PTSD, bipolar disorder, schizophrenia, and substance use disorders.

Article Title: Brain & Behavior Research Foundation Awards $1 Million for Groundbreaking Mental Health Research in 2026

News Publication Date: Not specified

Web References:
– https://bbrfoundation.org/
– https://www.instagram.com/woodnext/
– https://www.pbs.org/show/healthy-minds-with-dr-jeffrey-borenstein/

Image Credits: BBRF

Keywords: Mental health, neurobiology, depression, autism spectrum disorder, PTSD, bipolar disorder, schizophrenia, cocaine use disorder, chronic cannabis use, circadian rhythms, gene expression, neurosteroids, serotonin synthesis, neuroendocrine dysregulation, brain organoids, RNA therapeutics

Social behavior is inherently complex, involving dynamic choices about whom to engage with and how long to sustain interactions. For example, individuals preferentially attend to distressed friends, offering consolation, while simultaneously balancing attention between familiar and novel peers. These social decisions rely on finely tuned neural circuits. Previous studies have implicated disruptions in such circuitry in various psychiatric disorders, but the specific cellular components orchestrating these behaviors remained unclear until now.

Lead researcher TAKUMI Toru and his team employed advanced techniques combining genetic engineering and cutting-edge in vivo imaging to probe neuronal activity with unparalleled precision. By implanting miniature endoscopic cameras directly into the brains of genetically modified mice, the researchers could observe the activity of PV interneurons in real time during social encounters. These interneurons, known for their rapid firing and inhibitory control within neural networks, were hypothesized to modulate social preference behaviors.

The experimental design included selectively dampening the activity of PV interneurons via genetic modification to observe resultant behavioral changes. Remarkably, mice with inhibited PV interneurons displayed aberrant social recognition patterns. Unlike control mice, which spend less time with familiar conspecifics compared to strangers, these altered mice showed no such discrimination, engaging equally with both known and unknown peers. This finding indicates that PV interneurons play a critical role in encoding social familiarity, acting as a neural gatekeeper that influences social choice.

In addition to social recognition deficits, these PV-interneuron-inhibited mice failed to exhibit empathetic responses typically observed in healthy mice. When presented with a choice between a stressed peer and a non-stressed peer, normal mice preferentially approached and spent more time with the stressed individual—a behavior indicative of consolation or empathy. The genetically modified mice, however, did not demonstrate this preference, suggesting a breakdown in emotional recognition or processing pathways.

Intriguingly, when mice were allowed unrestricted social interaction without assigned choices, the inhibited group did not differ significantly in overall social behavior from their control counterparts. This nuanced observation suggests that PV interneurons do not govern social behavior broadly but selectively modulate the preference hierarchy and empathic bias within social networks. As a “switch” in the social brain network, these interneurons arbitrated targeted social decisions rather than general sociability.

These insights highlight the insular cortex’s PV interneurons as key modulators in the brain’s social information processing pipeline. The insular cortex functions as a hub for integrating sensory, emotional, and cognitive signals; therefore, disruptions in this circuitry could underpin the social cognition deficits frequently observed in neuropsychiatric disorders. Prior clinical observations have noted abnormalities in PV interneurons in postmortem analyses of brains from patients with schizophrenia and autism spectrum disorders, but direct causal links were lacking until now.

The methodological innovations of this study are noteworthy. The team’s use of genetic tools enabled selective suppression of targeted interneurons, while real-time imaging provided unprecedented resolution of neural dynamics during behavior. This approach allowed the researchers to correlate specific neuronal activity with discrete elements of social interaction, advancing our mechanistic understanding beyond correlational studies.

Beyond basic neuroscience, these findings pave the way for translational research targeting PV interneurons. By elucidating how these cells regulate social recognition and empathy, new therapeutic strategies could be developed to restore or modulate their function in patients suffering from social impairments. Modulating PV interneuron activity pharmacologically or via neuromodulation techniques may hold promise as interventions for autism or schizophrenia spectrum conditions.

Future research extending these findings to human subjects and other animal models will be imperative. Comparative studies could assess whether similar interneuronal circuits operate in human insular cortex and how genetic or environmental factors may alter their function during development. Such investigations can refine our understanding of the neural substrates of social cognition and identify biomarkers for early diagnosis.

This study was supported by extensive funding from multiple Japanese scientific organizations, including the Japan Society for the Promotion of Science, the Japan Agency for Medical Research and Development, and the Japan Science and Technology Agency. Collaborative efforts with Hokkaido University and Kyoto Institute of Technology underscore the interdisciplinary nature of this research endeavor.

Kobe University, renowned for its comprehensive research programs, continues to contribute substantially to neuroscience by integrating genetic, behavioral, and neuroimaging methodologies. Their work exemplifies the cutting-edge approaches required to unravel the complexities of social brain function and its disturbances in disease.

As the neuroscience community seeks to decode the biological basis of human sociality, the identification of PV interneurons as pivotal regulators opens new windows into the neural logic underlying empathy and social familiarity. Such insights not only deepen scientific knowledge but also bear significant societal relevance given the pervasive impact of social cognition disorders.

The promising trajectory established by Takumi and colleagues anticipates that therapeutic modulation of interneuron function in the insular cortex could one day mitigate the profound social impairments endured by millions worldwide. Understanding the cellular “switches” controlling social preference and empathetic behavior is an essential foundation for this transformative endeavor.

Subject of Research: Animals
Article Title: Parvalbumin interneurons in the insular cortex control social familiarity and emotion recognition
News Publication Date: 26-Aug-2025
Web References: http://dx.doi.org/10.1016/j.celrep.2025.116085
References: Cell Reports, DOI 10.1016/j.celrep.2025.116085
Image Credits: Kobe University, with material from Brennan Burling via Unsplash, Understanding Animal Research, National Institutes of Health
Keywords: parvalbumin interneurons, insular cortex, social behavior, empathy, neuropsychiatric disorders, autism spectrum disorder, schizophrenia, neuroscience, neural circuits, social cognition